WO2013038351A1 - Formes solides d'un inhibiteur de la dissociation de dérivés de transthyrétine - Google Patents

Formes solides d'un inhibiteur de la dissociation de dérivés de transthyrétine Download PDF

Info

Publication number
WO2013038351A1
WO2013038351A1 PCT/IB2012/054748 IB2012054748W WO2013038351A1 WO 2013038351 A1 WO2013038351 A1 WO 2013038351A1 IB 2012054748 W IB2012054748 W IB 2012054748W WO 2013038351 A1 WO2013038351 A1 WO 2013038351A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline form
compound
solid
peaks
raman
Prior art date
Application number
PCT/IB2012/054748
Other languages
English (en)
Inventor
Richard Frederic Labaudiniere
Michael Henry O'NEILL
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/345,111 priority Critical patent/US9249112B2/en
Priority to BR112014005810A priority patent/BR112014005810A2/pt
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to EP12780287.4A priority patent/EP2755961A1/fr
Priority to AU2012310157A priority patent/AU2012310157B2/en
Priority to KR1020147006603A priority patent/KR20140054231A/ko
Priority to CN201280043084.6A priority patent/CN103781770B/zh
Priority to RU2014109676/04A priority patent/RU2586330C2/ru
Priority to SG2014013270A priority patent/SG2014013270A/en
Priority to CA2847293A priority patent/CA2847293C/fr
Priority to MX2014003043A priority patent/MX2014003043A/es
Priority to NZ621194A priority patent/NZ621194B2/en
Priority to JP2014530354A priority patent/JP5869677B2/ja
Publication of WO2013038351A1 publication Critical patent/WO2013038351A1/fr
Priority to ZA2014/01202A priority patent/ZA201401202B/en
Priority to IL231472A priority patent/IL231472A0/en
Priority to HK14110758.5A priority patent/HK1197239A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Definitions

  • the present invention relates to solid forms of the N-methyl-D-glucamine
  • the invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.
  • This invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine (also referred to as "Compound 1 ”) that are useful in the treatment of transthyretin amyloid diseases, such as senile systemic amyloidosis (SSA), familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC), in mammals.
  • This invention also relates to compositions including such solid forms, and to methods of using such compositions in the treatment of transthyretin amyloid disease in mammals, especially humans.
  • Carboxy-2-phenyl-benzoxazoles such as 6-carboxy-2-(3,5-dichlorophenyl)- benzoxazole, and their salts, are described in U.S. Patent Nos. 7,214,695 and 7,214,696; and in U.S. Patent Application Publication No. 2010/0120919 (all of which are hereby incorporated by reference in their entireties). Methods of making carboxy-2-phenyl- benzoxazoles, as well as pharmaceutical compositions comprising the same, are also described therein.
  • Compound 1 stabilizes the protein transthyretin (TTR), dissociation of which is implicated in TTR amyloidosis (i.e., Compound 1 prevents dissociation of the native TTR tetramer into monomers, which results in the inhibition of TTR amyloid fibril formation) and is being developed for use in the treatment of transthyretin amyloid diseases.
  • TTR protein transthyretin
  • Solid forms are of interest to the pharmaceutical industry and especially to those involved in the development of suitable dosage forms. If the solid form is not held constant during clinical or stability studies, the exact dosage form used or studied may not be comparable from one lot to another. It is also desirable to have processes for producing a compound with the selected solid form in high purity when the compound is used in clinical studies or commercial products since impurities present may produce undesired toxicological effects. Certain solid forms may also exhibit enhanced thermodynamic stability or may be more readily manufactured in high purity in large quantities, and thus are more suitable for inclusion in pharmaceutical formulations. Certain solid forms may display other advantageous physical properties such as lack of hygroscopic tendencies, filterability, improved solubility, and enhanced rates of dissolution due to different lattice energies.
  • each solid form can be uniquely identified by several different analytical parameters, alone or in
  • One aspect of the present invention provides a crystalline form of 6-carboxy-2-(3,5- dichlorophenyl)-benzoxazole meglumine, represented as Compound 1 , wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2 ⁇ ) of 10.7 ⁇ 0.2, 1 1.8 ⁇ 0.2, and 13.3 ⁇ 0.2.
  • the crystalline form of Compound 1 has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2 ⁇ ) of 10.7 ⁇ 0.2, 1 1.8 ⁇ 0.2, 13.3 ⁇ 0.2, and 14.8 ⁇ 0.2.
  • the crystalline form of Compound 1 has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2 ⁇ ) of 10.7 ⁇ 0.2, 1 1.8 ⁇ 0.2, 13.3 ⁇ 0.2, 14.8 ⁇ 0.2 and 21.7 ⁇ 0.2.
  • Another aspect of the present invention provides a crystalline form of Compound 1 , wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2 ⁇ ) essentially the same as shown in Figure 1A.
  • Another aspect of the present invention provides a liquid crystalline form of
  • Another aspect of the present invention provides an amorphous form of Compound 1 , wherein said amorphous form has a powder X-ray diffraction peak position essentially the same as shown in Figure 3A.
  • Another aspect of the present invention provides an amorphous form of Compound 1 , wherein said amorphous form has a powder X-ray diffraction peak position essentially the same as shown in Figure 3B.
  • Another aspect of the present invention provides a liquid crystalline form of
  • Figure 1 depicts (a) a XRPD pattern of crystalline Compound 1 carried out on a Bruker D8 diffractometer and (b) a corresponding peak list.
  • amorphous refers to any solid substance which lacks order in three dimensions.
  • amorphous solids may be characterized by known techniques, including X-ray powder diffraction (XRPD) crystallography, solid state nuclear magnet resonance (ssNMR) spectroscopy, differential scanning calorimetry (DSC), or some combination of these techniques.
  • XRPD X-ray powder diffraction
  • ssNMR solid state nuclear magnet resonance
  • DSC differential scanning calorimetry
  • powder X-ray diffraction pattern or "PXRD pattern” refers to the experimentally observed diffractogram or parameters derived therefrom. Powder X-Ray diffraction patterns are characterized by peak position (abscissa) and peak intensities (ordinate).
  • 2 theta value or "2 ⁇ ” refers to the peak position in degrees based on the experimental setup of the X-ray diffraction experiment and is a common abscissa unit in diffraction patterns. The experimental setup requires that if a reflection is diffracted when the incoming beam forms an angle theta ( ⁇ ) with a certain lattice plane, the reflected beam is recorded at an angle 2 theta (2 ⁇ ).
  • the solid forms of Compound 1 can be characterized by one or more of the following: powder X-ray diffraction pattern (i.e., X-ray diffraction peaks at various diffraction angles (2 ⁇ )), solid state nuclear magnetic resonance (NMR) spectral pattern, Raman spectral diagram pattern, Infrared spectral pattern, aqueous solubility, light stability under International Conference on Harmonization (ICH) high intensity light conditions, and physical and chemical storage stability.
  • powder X-ray diffraction pattern i.e., X-ray diffraction peaks at various diffraction angles (2 ⁇ )
  • NMR solid state nuclear magnetic resonance
  • Raman spectral diagram pattern Raman spectral diagram pattern
  • Infrared spectral pattern aqueous solubility
  • ICH International Conference on Harmonization
  • Physical and chemical storage stability for example, a crystalline form, a two-dimensionally ordered liquid crystalline form and an amorphous form (discussed below) of Compound 1 were each
  • Peaks were manually identified using the Thermo Nicolet Omnic 7.4 software. Peak positions were picked at the peak maxima. Relative intensity values were classified as strong (S), medium (M) and weak (W) using the following criteria: strong (1.00-0.50); medium (0.49-0.10) and weak (0.09 and below).
  • the solid forms of the present invention can also be characterized using Infrared (IR) spectroscopy.
  • IR Infrared
  • the IR spectra were acquired using a Nicolet 6700 FTIR spectrometer equipped with a KBr beamsplitter and a d-TGS KBr detector.
  • a Specac Golden Gate Mk II single reflection diamond ATR accessory was used for sampling.
  • a nitrogen purge was connected to the IR bench as well as the ATR accessory.
  • the Golden Gate ATR anvil was in the up position when the air background is collected. Powder samples were compressed against the diamond window by the Golden Gate anvil. Approximately 50 cN-m of torque was applied to the sample when the anvil was completely compressed into the sample.
  • the different forms of the present invention can also be characterized using solid state NMR spectroscopy.
  • the 13 C solid state spectra for the crystalline and amorphous forms can be collected as follows. Approximately 80 mg of sample were tightly packed into a 4 mm Zr0 2 rotor. Spectra were collected on a Bruker-Biospin 4 mm CPMAS probe positioned into a wide- bore Bruker-Biospin Avance III 500 MHz ( 1 H frequency) NMR spectrometer. The packed rotor was oriented at the magic angle and spun at 15.0 kHz. The sample was cooled to 25.0 °C with a direct stream of nitrogen. The 13 C solid state spectra were collected using a proton decoupled cross-polarization magic angle spinning (CPMAS) experiment. The cross-polarization contact time was set to 2.0 ms. A proton decoupling field of
  • crystalline forms of a given compound can exist in substantially pure forms of a single polymorph, but can also exist in a crystalline form that comprises two or more different polymorphs or amorphous forms.
  • a solid form comprises two or more polymorphs
  • the X-ray diffraction pattern will have peaks characteristic of each of the individual polymorphs of the present invention.
  • a solid form that comprises two polymorphs will have a powder X-ray diffraction pattern that is a convolution of the two X-ray diffraction patterns that correspond to the substantially pure solid forms.
  • a solid form of Compound 1 can contain a first and second solid form where the solid form contains at least 10% by weight of the first polymorph.
  • the solid form contains at least 20% by weight of the first polymorph. Even further examples contain at least 30%, at least 40%, or at least 50% by weight of the first polymorph.
  • One of skill in the art will recognize that many such combinations of several individual polymorphs and amorphous forms in varying amounts are possible.
  • a crystalline form of Compound 1 is a fully crystalline, non-hygroscopic, anhydrous, mono-meglumine salt form that can be produced as described in Example 1 .
  • this form has advantages over the free acid and other solid forms of Compound 1 .
  • the crystalline form has improved solubility (>3.4 mg/mL in unbuffered water) compared to the free acid ( ⁇ 1 1 ug/mL in unbuffered water.
  • the crystalline form has improved handling properties, as it is non-hygroscopic.
  • the crystalline form of Compound 1 was also characterized by the Raman spectral pattern shown in Figure 4A, which was carried out on a Nicolet NXR FT-Raman
  • the crystalline form of Compound 1 was also characterized by the infrared spectral pattern shown in Figure 7A, which was carried out on a Nicolet 6700 FTIR spectrometer equipped with a KBr beamsplitter and a d-TGS KBR detector. The infrared spectral peaks of the crystalline form of Compound 1 are shown in Figure 7B.
  • a liquid crystalline form of Compound 1 can be produced as described in Example 2.
  • the liquid crystalline form of Compound 1 was also characterized by the solid state NMR spectral pattern shown in Figure 1 1 A, which was carried out on a Bruker-Biospin 4 mm CPMAS probe positioned into a wide-bore Bruker-Biospin Avance III 500 MHz NMR spectrometer.
  • the 13 C chemical shifts of the liquid crystalline form of Compound 1 are shown in Figure 1 1 B.
  • the amorphous form of Compound 1 was also characterized by the Raman spectral pattern shown in Figure 6A, which was carried out on a Nicolet NXR FT-Raman
  • the amorphous form of Compound 1 was also characterized by the infrared spectral pattern shown in Figure 9A, which was carried out on a Nicolet 6700 FTIR spectrometer equipped with a KBr beamsplitter and a d-TGS KBR detector. The infrared spectral peaks of the amorphous form of Compound 1 are shown in Figure 9B.
  • the amorphous form of Compound 1 was also characterized by the solid state NMR spectral pattern shown in Figure 12A, which was carried out on a Bruker-Biospin 4 mm CPMAS probe positioned into a wide-bore Bruker-Biospin Avance II I 500 MHz NMR spectrometer. The 13 C chemical shifts of the amorphous form of Compound 1 are shown in Figure 12B.
  • the active agents (i.e., the solid forms of Compound 1 described herein) of the invention may be formulated into pharmaceutical compositions suitable for mammalian medical use. Any suitable route of administration may be employed for providing a patient with an effective dosage of any of the solid forms of Compound 1.
  • peroral or parenteral formulations and the like may be employed.
  • Dosage forms include capsules, tablets, dispersions, suspensions and the like, e.g. enteric-coated capsules and/or tablets, capsules and/or tablets containing enteric-coated pellets of Compound 1.
  • solid forms of Compound 1 can be admixed with other suitable constituents.
  • the compositions may be conveniently presented in unit dosage forms, and prepared by any methods known in the pharmaceutical arts.
  • compositions of the invention comprise a therapeutically effective amount of the active agent and one or more inert, pharmaceutically acceptable carriers, and optionally any other therapeutic ingredients, stabilizers, or the like.
  • the carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.
  • compositions may further include diluents, buffers, binders, disintegrants, thickeners, lubricants, preservatives (including antioxidants), flavoring agents, taste-masking agents, inorganic salts (e.g., sodium chloride), antimicrobial agents (e.g., benzalkonium chloride), sweeteners, antistatic agents, surfactants (e.g., polysorbates such as 'TWEEN 20 TM " and 'TWEEN 80 TM “, and Pluronic ® F68 and F88, available from BASF), sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines, fatty acids and fatty esters, steroids (e.g., cholesterol)), and chelating agents (e.g., EDTA, zinc and other such suitable cations).
  • the active agents of the invention may be formulated in compositions including those suitable for oral, rectal, topical, nasal, ophthalmic, or parenteral (including intraperitoneal, intravenous, subcutaneous, or intramuscular injection) administration.
  • the amount of the active agent in the formulation will vary depending upon a variety of factors, including dosage form, the condition to be treated, target patient population, and other considerations, and will generally be readily determined by one skilled in the art.
  • a therapeutically effective amount will be an amount necessary to inhibit transthyretin (TTR) dissociation (i.e. prevents dissociation of the native TTR tetramer into monomers).
  • TTR transthyretin
  • compositions will generally contain anywhere from about 0.001 % by weight to about 99% by weight active agent, preferably from about 0.01 % to about 5% by weight active agent, and more preferably from about 0.01 % to 2% by weight active agent, and will also depend upon the relative amounts of excipients/additives contained in the composition.
  • a pharmaceutical composition of the invention is administered in conventional dosage form prepared by combining a therapeutically effective amount of an active agent as an active ingredient with one or more appropriate pharmaceutical carrier according to conventional procedures. These procedures may involve mixing granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the pharmaceutical carrier(s) employed may be either solid or liquid.
  • Exemplary solid carriers include lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesiun stearate, stearic acid and the like.
  • Exemplary liquid carriers include syrup, peanut oil olive oil, water and the like.
  • the carrier(s) may include time-delay or time release materials known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylatt and the like.
  • a variety of pharmaceutical forms can be employed.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier may vary, but generally will be from about 25 mg to about 1 g.
  • the preparation can be in the form of syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an ampoule or vial or non-aqueous liquid suspension.
  • a pharmaceutically acceptable salt of an active agent can be dissolved in an aqueous solution of an organic or inorganic base, such as a 0.3 M solution of meglumine.
  • the active agent may be dissolved in a suitable co-solvent or combinations of co-solvents.
  • suitable co-solvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, gylcerin and the like in concentrations ranging from 0-60% of the total volume.
  • the composition may also be in the form of a solution of a salt form of the active agent in an appropriate aqueous vehicle such as water or isotonic saline or dextrose solution.
  • compositions of this invention will vary according to the particular solid form being used, the particular composition formulated, the mode of administration and the particular site, host and disease being treated. Those skilled in the art using conventional dosage-determination tests in view of the experimental data for an agent can ascertain optimal dosages for a given set of conditions.
  • an exemplary daily dose generally employed is from about 0.001 to about 1000 mg/kg of body weight, more preferably from about 0.001 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals.
  • Administration of prodrugs is typically dosed at weight levels that are chemically equivalent to the weight levels of the fully active form.
  • the most suitable route of administration as well as the magnitude of a therapeutic dose will depend on the nature and severity of the disease to be treated.
  • a solid form of Compound 1 can be formulated by combining the active agent with pharmaceutically acceptable carriers known in the art.
  • Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • compositions for oral use can be obtained using a solid excipient in admixture with the active agent, optionally grinding the resulting mixture, and processing the mixture of granules after adding suitable auxiliaries.
  • suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; and cellulose preparations, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or
  • PVP polyvinylpyrrolidone
  • disintegrating agents such as crosslinked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and, optionally, stabilizers.
  • the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the active agent is delivered in a pharmaceutically acceptable ophthalmic vehicle such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye, including, for example, the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/cilary, lens, choroid/retina and selera.
  • the pharmaceutically acceptable ophthalmic vehicle may be, for example, an ointment, vegetable oil, or an encapsulating material.
  • An active agent of the invention may also be injected directly into the vitreous and aqueous humor or subtenon.
  • the solid forms may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
  • the solid forms may be formulated with suitable polymeric or
  • hydrophobic materials for example, as an emulsion in an acceptable oil
  • ion-exchange resins for example, ion-exchange resins
  • sparingly soluble derivatives for example, as a sparingly soluble salt.
  • solid forms of Compound 1 may be delivered using a sustained-release system, such as semi-permeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials have been established and are known by those skilled in the art.
  • 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole alone can form a gel on contact with aqueous vehicles, such as water, phosphate buffer and hydrochloric acid.
  • aqueous vehicles such as water, phosphate buffer and hydrochloric acid.
  • compositions of solid forms of Compound 1 (6-carboxy-2-(3,5- dichlorophenyl)-benzoxazole meglumine) that surprisingly can be comparatively resistant to gel formation and stomach compaction, and can have comparatively greater dissolution and bioavailability, and can deliver drug levels proportional to the administered dose.
  • the pharmaceutical compositions of Compound 1 can be stable to accelerated aging conditions, such as elevated temperature and humidity.
  • the pharmaceutical compositions herein are also contemplated for use in or further combination with any conventional formulation or route or method of administration where contact with water or other aqueous vehicles may occur, e.g., contact with blood or other body fluids as in various forms of parenteral administration (e.g., contact with blood in intravenous administration, implants, and the like), contact with mucous membranes (e.g., suppositories via vaginal or rectal administration, dry powder aerosols for pulmonary administration, transdermal patches or lozenges applied to mucous membranes, and the like).
  • parenteral administration e.g., contact with blood in intravenous administration, implants, and the like
  • mucous membranes e.g., suppositories via vaginal or rectal administration, dry powder aerosols for pulmonary administration, transdermal patches or lozenges applied to mucous membranes, and the like.
  • the benefits of the certain pharmaceutical compositions such as resistance to gel formation, greater dissolution and bioavailability, dose
  • the pharmaceutical composition comprise a solid form of Compound 1 and a polyethylene glycol having an average molecular weight of between about 100 and about 1000, characterized in that the solid form in the
  • composition has, compared to the solid form alone, a greater dispersibility in water or greater resistance to gel formation on contact with water.
  • the molecular weight of the polyethylene glycol is about 400.
  • the invention relates to any of the aforementioned pharmaceutical compositions, wherein said composition comprises PEG 400, Span TM 80 and/or polysorbate 80.
  • the invention relates to any of the aforementioned pharmaceutical compositions, wherein said solid form of Compound 1 is the crystalline form. In certain embodiments, the invention relates to any of the aforementioned pharmaceutical compositions, wherein said solid form of Compound 1 is the liquid crystalline form. In certain embodiments, the invention relates to any of the aforementioned pharmaceutical compositions, wherein said solid form of Compound 1 is the amorphous form.
  • the solid forms of Compound 1 may be packaged as articles of manufacture containing packaging material, a solid form of Compound 1 as provided herein, which is effective for modulating TTR folding, or for treatment, prevention or amelioration of one or more symptoms of TTR mediated diseases or disorders, or diseases or disorders in which TTR misfolding, is implicated, within the packaging material, and a label that indicates that the solid form of Compound 1 is used for modulating TTR folding, or for treatment, prevention or amelioration of one or more symptoms of TTR mediated diseases or disorders, or diseases or disorders in which TTR misfolding is implicated.
  • packaging materials for use in packaging pharmaceutical products are well known to those of skill in the art. See, e.g., U.S. Patent Nos. 5,323,907, 5,052,558 and 5,033,252.
  • Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
  • the invention relates to any of the aforementioned articles of manufacture, wherein said solid form of Compound 1 is the crystalline form. In certain embodiments, the invention relates to any of the aforementioned articles of manufacture, wherein said solid form of Compound 1 is the liquid crystalline form. In certain embodiments,
  • the invention relates to any of the aforementioned articles of manufacture, wherein said solid form of Compound 1 is the amorphous form.
  • a number of in vitro tests can be used to evaluate the solid forms for their ability to stabilize transthyretin tetramers or prevent formation of fibrils.
  • the tests can include a fibril formation assay, a plasma selectivity assay, determination of the three-dimensional structure of a transthyretin compound complex (e. g. by X-ray crystallography), kinetics of transthyretin tetramer dissociation or fibril formations, and determining the stoichiometry and energetics of transthyretin compound interactions, by, for example, centrifugation or calorimetry. Details of exemplary in vitro assays are provided in U.S. Patent Nos. 7,214,695 and 7,214,696; and in U.S. Patent Application Publication No. 2010/0120919 (all of which are hereby incorporated by reference in their entireties).
  • Solid forms of Compound 1 are useful for stabilizing the protein transthyretin (TTR), dissociation of which is implicated in TTR amyloidosis (i.e., prevents dissociation of the native TTR tetramer into monomers, which results in the inhibition of TTR amyloid fibril formation), thus providing treatments for transthyretin amyloid diseases in mammals, including humans.
  • TTR protein transthyretin
  • At least some amyloid diseases appear to be caused by the deposition of any one of more than 20 nonhomologous proteins or protein fragments, ultimately affording a fibrillar cross-3-sheet quaternary structure.
  • Formation of amyloid fibrils from a normally folded protein like transthyretin requires protein misfolding to produce an assembly-competent intermediate.
  • the process of transthyretin (TTR) amyloidogenesis appears to cause senile systemic amyloidosis (SSA), familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC).
  • SSA senile systemic amyloidosis
  • FAP familial amyloid polyneuropathy
  • FAC familial amyloid cardiomyopathy
  • TTR amyloid diseases include cardiac amyloidosis following liver transplantation, peripheral nerve amyloidosis following liver transplantation, leptomeningeal amyloidosis, transthyretin mutant-associated carpal tunnel syndrome, vitreous deposition, and transthyretin mutant- associated skin amyloidosis.
  • Therapeutically effective amounts of Compound 1 may be administered, typically in the form of a pharmaceutical composition, to treat diseases mediated by modulation or regulation of TTR dissociation.
  • An "effective amount” is intended to mean that amount of an agent that, when administered to a mammal in need of such treatment, is sufficient to effect treatment for a disease mediated by TTR dissociation.
  • a therapeutically effective amount of Compound 1 is a quantity sufficient to modulate, regulate, or inhibit the dissociation of TTR such that a disease condition that is mediated by that activity is reduced or alleviated.
  • Treating is intended to mean at least the mitigation of a disease condition in a mammal, such as a human, and includes: preventing the disease condition from occurring in a mammal, particularly when the mammal is found to be predisposed to having the disease condition but has not yet been diagnosed as having it; modulating and/or inhibiting the disease condition; and/or alleviating the disease condition.
  • Exemplary disease conditions include senile systemic amyloidosis (SSA), familial amyloid polyneuropathy (FAP), familial amyloid cardiomyopathy (FAC), cardiac amyloidosis following liver transplantation, peripheral nerve amyloidosis following liver transplantation, leptomeningeal amyloidosis, transthyretin mutant-associated carpal tunnel syndrome, vitreous deposition, and transthyretin mutant-associated skin amyloidosis.
  • SSA systemic amyloidosis
  • FAP familial amyloid polyneuropathy
  • FAC familial amyloid cardiomyopathy
  • cardiac amyloidosis following liver transplantation peripheral nerve amyloidosis following liver transplantation
  • leptomeningeal amyloidosis transthyretin mutant-associated carpal tunnel syndrome
  • vitreous deposition vitreous deposition
  • transthyretin mutant-associated skin amyloidosis transthyretin mutant-associated skin amyloidosis
  • 6-Carboxy-2-(3,5-dichlorophenyl)-benzoxazole free acid (2.5 g, 8.1 mmol) and 2- propanol (49 ml.) were charged to a 100 mL jacketed, 2-neck round bottom flask with magnetic stirrer. The resulting slurry was warmed to 70 °C with stirring. Water (8.8 mL) was then charged. In a separate 15 mL round bottom flask a solution of N-methyl-D- glucamine (1.58 g, 8.1 mmol) in 5 mL water was prepared and dissolved with stirring. The aqueous N-methyl-D-glucamine solution was then transferred to the reaction flask over 2 min.
  • the solution was transferred to a lyophlization vessel and frozen while rotated in an acetone/dry ice bath.
  • the vessel was transferred to a bench-top freeze dryer and allowed to dry under vacuum for approximately 19 hours, producing a white solid.
  • Crystalline Compound 1 (approximately 500 mg) was transferred to an aluminum pan and placed on a 200 °C hot plate. Melting occurred within 1 minute, at which point the pan was removed from the hot plate and immediately placed in liquid nitrogen. A glassy solid resulted.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention porte sur des formes solides du sel de N-méthyl-D-glucamine (méglumine) du 6-carboxy-2-(3,5-dichlorophényl)benzoxazole et sur des procédés pour leur préparation. L'invention porte également sur des compositions pharmaceutiques contenant au moins une telle forme solide et sur l'utilisation thérapeutique ou prophylactique de telles formes solides et compositions.
PCT/IB2012/054748 2011-09-16 2012-09-12 Formes solides d'un inhibiteur de la dissociation de dérivés de transthyrétine WO2013038351A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA2847293A CA2847293C (fr) 2011-09-16 2012-09-12 Formes solides d'un inhibiteur de la dissociation de derives de transthyretine
SG2014013270A SG2014013270A (en) 2011-09-16 2012-09-12 Solid forms of a transthyretin dissociation inhibitor
EP12780287.4A EP2755961A1 (fr) 2011-09-16 2012-09-12 Formes solides d'un inhibiteur de la dissociation de dérivés de transthyrétine
BR112014005810A BR112014005810A2 (pt) 2011-09-16 2012-09-12 formas sólidas de um inibidor da dissociação de transtirretina
KR1020147006603A KR20140054231A (ko) 2011-09-16 2012-09-12 트랜스티레틴 해리 억제제의 고체 형태
CN201280043084.6A CN103781770B (zh) 2011-09-16 2012-09-12 转甲状腺素蛋白解离抑制剂的固体形式
MX2014003043A MX2014003043A (es) 2011-09-16 2012-09-12 Formas solidas de un inhibidor de disociacion transtiretina.
US14/345,111 US9249112B2 (en) 2011-09-16 2012-09-12 Solid forms of a transthyretin dissociation inhibitor
AU2012310157A AU2012310157B2 (en) 2011-09-16 2012-09-12 Solid forms of a transthyretin dissociation inhibitor
RU2014109676/04A RU2586330C2 (ru) 2011-09-16 2012-09-12 Твердые формы ингибитора диссоциации транстиретина
NZ621194A NZ621194B2 (en) 2011-09-16 2012-09-12 Solid forms of a transthyretin dissociation inhibitor
JP2014530354A JP5869677B2 (ja) 2011-09-16 2012-09-12 トランスサイレチン解離阻害剤の固体形態
ZA2014/01202A ZA201401202B (en) 2011-09-16 2014-02-18 Solid forms of a transthyretin dissociation inhibitor
IL231472A IL231472A0 (en) 2011-09-16 2014-03-12 Crystal structures of transthyretin dissociation inhibitor
HK14110758.5A HK1197239A1 (zh) 2011-09-16 2014-10-27 轉甲狀腺素蛋白解離抑制劑的固體形式

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535551P 2011-09-16 2011-09-16
US61/535,551 2011-09-16

Publications (1)

Publication Number Publication Date
WO2013038351A1 true WO2013038351A1 (fr) 2013-03-21

Family

ID=47116132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/054748 WO2013038351A1 (fr) 2011-09-16 2012-09-12 Formes solides d'un inhibiteur de la dissociation de dérivés de transthyrétine

Country Status (17)

Country Link
US (2) US9249112B2 (fr)
EP (1) EP2755961A1 (fr)
JP (2) JP5869677B2 (fr)
KR (1) KR20140054231A (fr)
CN (1) CN103781770B (fr)
AR (1) AR088755A1 (fr)
AU (1) AU2012310157B2 (fr)
BR (1) BR112014005810A2 (fr)
CA (1) CA2847293C (fr)
HK (1) HK1197239A1 (fr)
IL (1) IL231472A0 (fr)
MX (1) MX2014003043A (fr)
RU (1) RU2586330C2 (fr)
SG (1) SG2014013270A (fr)
TW (2) TWI476185B (fr)
WO (1) WO2013038351A1 (fr)
ZA (1) ZA201401202B (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
WO2016038500A1 (fr) * 2014-09-08 2016-03-17 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole
EP3453703A4 (fr) * 2016-05-05 2019-03-20 Crystal Pharmatech Co., Ltd Forme cristalline e d'un sel de tafamidis méthylglucamine, son procédé de préparation et son application
WO2019175263A1 (fr) * 2018-03-13 2019-09-19 Azad Pharma Ag Nouveaux polymorphes et nouvelle voie de synthèse de tafamidis
WO2020207753A1 (fr) 2019-04-11 2020-10-15 Inke, S.A. Procédé de préparation de 1-désoxy-1-méthylamino-d-glucitol 2-(3,5-dichlorophényl)-6-benzoxazolecarboxylate
WO2021019448A1 (fr) * 2019-08-01 2021-02-04 Honour (R&D) Procédé de préparation d'un inhibiteur de la dissociation de la transthyrétine
WO2022009221A1 (fr) * 2020-07-04 2022-01-13 Nuray Chemicals Private Limited Formes à l'état solide de 6-carboxy-2-(3, 5-dichlorophényl)-benzoxazole de formule i et leurs sels pharmaceutiquement acceptables
EP4083027A1 (fr) 2021-04-26 2022-11-02 Química Sintética, S.A. Forme de tafamidis à l'état solide et son procédé de préparation
WO2023020762A1 (fr) 2021-08-16 2023-02-23 Synthon B.V. Formes cristallines d'un produit d'addition de tafamidis nicotinamide
US11795152B2 (en) 2019-11-15 2023-10-24 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of tafamidis and preparation method therefor and use thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06105459B2 (ja) * 1988-08-11 1994-12-21 日本電気株式会社 ベクトル処理装置
JP5869677B2 (ja) * 2011-09-16 2016-02-24 ファイザー・インク トランスサイレチン解離阻害剤の固体形態
US20220071965A1 (en) 2018-12-20 2022-03-10 Pfizer Inc. Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
CN113993853A (zh) 2019-05-16 2022-01-28 梯瓦制药国际有限责任公司 氯苯唑酸及其盐的固态形式
EP4077287A1 (fr) 2019-12-20 2022-10-26 Pfizer Ireland Pharmaceuticals Procédé efficace de fabrication de dérivés de 6-carboxy benzoxazole
WO2021232619A1 (fr) * 2020-05-19 2021-11-25 苏州科睿思制药有限公司 Forme cristalline de l'acide libre tafamidis, son procédé de préparation et son utilisation
WO2022112919A1 (fr) 2020-11-25 2022-06-02 Pfizer Inc. Composés de pyrazole substitués par (aza)benzothiazolyle
WO2023091534A1 (fr) 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Forme à l'état solide de tafamidis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7214696B2 (en) 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602336C (de) 1933-03-09 1934-09-06 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Kuepenfarbstoffen der Anthrachinonreihe
US3551433A (en) 1967-06-21 1970-12-29 Us Army Preparation of 4-phenyl-4-acyloxypiperidine
US3551443A (en) 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
USRE29608E (en) 1972-05-18 1978-04-11 Lilly Industries Limited Benzoxazole derivatives
DE2314238A1 (de) 1973-03-22 1974-09-26 Henkel & Cie Gmbh Neue 2-(tetrazol-5'-yl)-benzoxazole, deren herstellung sowie verwendung als entzuendungshemmer in kosmetischen praeparationen
GB1488003A (en) * 1973-10-23 1977-10-05 Lilly Industries Ltd 1,2-benzisoxazole derivatives processes for their preparation and their use as pharmaceuticals
US4025637A (en) 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US4025636A (en) 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
DE2619547A1 (de) 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4416892A (en) 1981-04-23 1983-11-22 Lilly Industries Limited Method of treating hypersensitivity disease with benzoxazole derivatives
US5254692A (en) 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
DE4011106A1 (de) 1990-04-06 1991-10-10 Bayer Ag Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
CA2051518A1 (fr) 1990-10-01 1992-04-02 Robert J. Perry Synthese de composes heterocycliques
CH681806A5 (fr) 1991-03-19 1993-05-28 Ciba Geigy Ag
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
GB9218334D0 (en) 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5837390A (en) 1995-05-10 1998-11-17 Sony Corporation Metal complex, method for producing the same and optical device
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
FR2767527B1 (fr) 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
EP1053237B1 (fr) 1998-02-04 2003-07-02 The Board Of Regents, The University Of Texas System Inhibition de telomerase humaine par un compose d'interaction avec g-quadruplex
US6107491A (en) 1998-07-20 2000-08-22 Ciba Specialty Chemicals Corporation Polymerizable diketopyrrolopyrroles
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
CN1356988A (zh) 1999-06-18 2002-07-03 拜尔公司 苯氧基氟代嘧啶类化合物
WO2001012183A1 (fr) 1999-08-16 2001-02-22 Merck & Co., Inc. Amides heterocycles comme inhibiteurs de l'adhesion cellulaire
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
PL207869B1 (pl) 2000-03-16 2011-02-28 Hoffmann La Roche Pochodne kwasu karboksylowego, środek farmaceutyczny i sposób wytwarzania pochodnych kwasu karboksylowego
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
ES2395721T3 (es) 2000-08-24 2013-02-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Derivados de tioflavina y su uso en diagnosis y terapia de la enfermedad de alzheimer
EP1330432A2 (fr) 2000-11-04 2003-07-30 Aventis Pharma Limited Acides alcanoiqies substitues
US20070004713A1 (en) 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
US7045539B2 (en) 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
GB0118357D0 (en) 2001-07-27 2001-09-19 Syngenta Ltd Chemical compounds
WO2003020698A2 (fr) 2001-09-06 2003-03-13 Prochon Biotech Ltd. Inhibiteurs de la tyrosine kinase
US6602619B2 (en) 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
KR100919147B1 (ko) 2001-11-16 2009-09-25 닛뽕 케미파 가부시키가이샤 크산틴 옥시다제 저해제
EP1478631A1 (fr) 2001-11-28 2004-11-24 AstraZeneca AB Composes therapeutiques
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1465854A4 (fr) 2001-12-19 2005-06-08 Atherogenics Inc Derives de chalcone et leur utilisation dans le traitement de maladies
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
MXPA04009040A (es) 2002-03-20 2005-01-25 Metabolex Inc Acidos fenilaceticos sustituidos.
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0226822D0 (en) 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
EP1587798A4 (fr) 2003-01-14 2007-06-27 Merck & Co Inc Derives de nsaid a disubstitution geminale servant d'agents reducteurs de abeta 42
CA2438032C (fr) 2003-03-14 2013-05-07 University Of Pittsburgh Derives de benzothiazole et compositions et utilisations connexes
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
AU2004224392A1 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
CA2520804A1 (fr) 2003-04-03 2004-10-28 Merck & Co., Inc. Pyrazoles biaryle substitue utilises en tant que bloqueurs de canaux sodiques
CN1805945A (zh) 2003-04-18 2006-07-19 麦克公司 作为钠通道阻滞剂的联芳基取代的噻唑、噁唑和咪唑
WO2004098494A2 (fr) 2003-04-30 2004-11-18 Cytokinetics, Inc. Composés, compositions et procédés
WO2005113523A1 (fr) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. Composés 2-(hétéroaryl)benzoxazoles et dérivés, compositions et procédés servant à stabiliser la transthyrétine et à inhiber le mauvais repliement de la transthyrétine
WO2011116123A1 (fr) 2010-03-19 2011-09-22 Irm Llc Tafamidis pour le traitement de troubles ophtalmiques
JP5869677B2 (ja) * 2011-09-16 2016-02-24 ファイザー・インク トランスサイレチン解離阻害剤の固体形態
WO2013166041A1 (fr) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Ligands de la transthyrétine pouvant inhiber l'interaction de rbp4-ttr dépendante du rétinol pour le traitement de la dégénérescence maculaire liée à l'âge, de la maladie de stargardt et d'autres maladies de la rétine caractérisées par une accumulation excessive de lipofuscine
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7214696B2 (en) 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US7214695B2 (en) 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US20100120919A1 (en) 2002-12-19 2010-05-13 Kelly Jeffery W Methods for treating transthyretin amyloid diseases

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients, 3rd. Ed., E", 2000, PHARMACEUTICAL PRESS
"Physician's Desk Reference, 52nd ed.,", 1998, MEDICAL ECONOMICS
"Remington: The Science & Practice of Pharmacy, 19th ed.,", 1995, WILLIAMS & WILLIAMS
ANDERSON ET AL: "TOOLS FOR PURIFYING THE PRODUCT: COLUMN CHROMATOGRAPHY, CRYSTALLIZATION AND RESLURRYING", PRACTICAL PROCESS RESEARCH AND DEVELOPMENT, ACADEMIC PRESS, SAN DIEGO, US, 1 January 2000 (2000-01-01), pages 223 - 247, XP002382432 *
BUXBAUM, J. N.; TAGOE, C. E., ANN. REV. MED., vol. 51, 2000, pages 543 - 569
BYRN S ET AL: "PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, vol. 12, no. 7, 1 July 1995 (1995-07-01), pages 945 - 954, XP000996386, ISSN: 0724-8741, DOI: 10.1023/A:1016241927429 *
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: 10.1007/3-540-69178-2_5 *
COLON, W.; KELLY, J. W., BIOCHEMISTRY, vol. 31, 1992, pages 8654 - 60
FERRER, N.; NOGUÉS-CARULLA, J.M., DIAMOND AND RELATED MATERIALS, vol. 5, 1996, pages 598 - 602
HARWOOD L M ET AL: "Experimental organic chemistry - Principles and practice", 1 January 1989, EXPERIMENTAL CHEMISTRY - ORGANIC CHEMISTRY AND REACTION,, PAGE(S) 127 - 132, ISBN: 978-0-632-02016-4, XP003025361 *
JACOBSON, D. R. ET AL., N. ENGL. J. MED., vol. 336, 1997, pages 466 - 73
KELLY, J. W., CURR. OPIN. STRUCT. BIOL., vol. 6, 1996, pages 11 - 7
LIU, K. ET AL., NAT. STRUCT. BIOL, vol. 7, 2000, pages 754 - 7
MARK RATNER: "Spotlight focuses on protein-misfolding therapies", NATURE BIOTECHNOLOGY, vol. 27, no. 10, 1 October 2009 (2009-10-01), pages 874 - 874, XP055044618, ISSN: 1087-0156, DOI: 10.1038/nbt1009-874c *
PIKE TECHNOLOGIES TECHNICAL NOTE: PIKE REFLECTIONS, vol. 7/1, 2002, Retrieved from the Internet <URL:www.piketech.com>
S. E. KOLSTOE ET AL: "Trapping of palindromic ligands within native transthyretin prevents amyloid formation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 47, 23 November 2010 (2010-11-23), pages 20483 - 20488, XP055044617, ISSN: 0027-8424, DOI: 10.1073/pnas.1008255107 *
SARAIVA, M. J. ET AL., J. CLIN. INVEST., vol. 76, 1985, pages 2171 - 7
SARAIVA, M. J., HUM. MUTAT., vol. 5, 1995, pages 191 - 6
See also references of EP2755961A1
THONGNOPKUN, P.; EKGASIT, S., DIAMOND AND RELATED MATERIALS, vol. 14, 2005, pages 1592 - 1599
WESTERMARK, P. ET AL., PROC. NATL. ACAD. SCI. U. S. A., vol. 87, 1990, pages 2843 - 5

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
KR102004059B1 (ko) * 2014-09-08 2019-07-25 화이자 인코포레이티드 6-카르복시-2-(3,5-디클로로페닐)-벤족사졸의 고체 결정형
JP2016065042A (ja) * 2014-09-08 2016-04-28 ファイザー・インク ６−カルボキシ−２−（３，５−ジクロロフェニル）−ベンゾオキサゾールの結晶性固体形態
KR20170040314A (ko) * 2014-09-08 2017-04-12 화이자 인코포레이티드 6-카르복시-2-(3,5-디클로로페닐)-벤족사졸의 결정질 고체 형태
US9770441B1 (en) 2014-09-08 2017-09-26 Pfizer Inc. Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
AU2015313875B2 (en) * 2014-09-08 2018-03-15 Pfizer Inc. Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
RU2692252C2 (ru) * 2014-09-08 2019-06-24 Пфайзер Инк. Кристаллические твердые формы 6-карбокси-2-(3,5-дихлорфенил)бензоксазола
EP3191461B1 (fr) 2014-09-08 2021-11-03 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole
WO2016038500A1 (fr) * 2014-09-08 2016-03-17 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole
EP4349406A3 (fr) * 2014-09-08 2024-05-22 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole pour l'utilisation comme médicaments
EP3977993A1 (fr) * 2014-09-08 2022-04-06 Pfizer Inc. Formes cristallines solides du 6-carboxy-2-(3,5-dichlorophényl)-benzoxazole pour l'utilisation comme médicaments
EP3453703A4 (fr) * 2016-05-05 2019-03-20 Crystal Pharmatech Co., Ltd Forme cristalline e d'un sel de tafamidis méthylglucamine, son procédé de préparation et son application
US20190119226A1 (en) * 2016-05-05 2019-04-25 Crystal Pharmatech Co., Ltd. Crystalline form e of tafamidis meglumine, process for preparation and use thereof
US10577334B2 (en) * 2016-05-05 2020-03-03 Crystal Pharmatech Co., Ltd. Crystalline form E of tafamidis meglumine, process for preparation and use thereof
WO2019175263A1 (fr) * 2018-03-13 2019-09-19 Azad Pharma Ag Nouveaux polymorphes et nouvelle voie de synthèse de tafamidis
US11208391B2 (en) 2018-03-13 2021-12-28 Azad Pharma Ag Polymorphs and new path to synthesize Tafamidis
WO2020207753A1 (fr) 2019-04-11 2020-10-15 Inke, S.A. Procédé de préparation de 1-désoxy-1-méthylamino-d-glucitol 2-(3,5-dichlorophényl)-6-benzoxazolecarboxylate
WO2021019448A1 (fr) * 2019-08-01 2021-02-04 Honour (R&D) Procédé de préparation d'un inhibiteur de la dissociation de la transthyrétine
US11795152B2 (en) 2019-11-15 2023-10-24 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of tafamidis and preparation method therefor and use thereof
WO2022009221A1 (fr) * 2020-07-04 2022-01-13 Nuray Chemicals Private Limited Formes à l'état solide de 6-carboxy-2-(3, 5-dichlorophényl)-benzoxazole de formule i et leurs sels pharmaceutiquement acceptables
EP4083027A1 (fr) 2021-04-26 2022-11-02 Química Sintética, S.A. Forme de tafamidis à l'état solide et son procédé de préparation
WO2022229026A1 (fr) 2021-04-26 2022-11-03 Quimica Sintetica, S. A. Forme solide de tafamidis et son procédé de préparation
WO2023020762A1 (fr) 2021-08-16 2023-02-23 Synthon B.V. Formes cristallines d'un produit d'addition de tafamidis nicotinamide

Also Published As

Publication number Publication date
CN103781770B (zh) 2016-04-13
CA2847293A1 (fr) 2013-03-21
RU2014109676A (ru) 2015-10-27
ZA201401202B (en) 2016-01-27
TW201315720A (zh) 2013-04-16
JP2014526498A (ja) 2014-10-06
TWI476185B (zh) 2015-03-11
JP2016128444A (ja) 2016-07-14
SG2014013270A (en) 2014-05-29
AU2012310157A1 (en) 2014-04-03
CN103781770A (zh) 2014-05-07
EP2755961A1 (fr) 2014-07-23
AU2012310157B2 (en) 2015-11-12
BR112014005810A2 (pt) 2017-03-28
MX2014003043A (es) 2015-02-05
NZ621194A (en) 2016-02-26
TWI538909B (zh) 2016-06-21
JP5869677B2 (ja) 2016-02-24
AR088755A1 (es) 2014-07-02
IL231472A0 (en) 2014-04-30
US9249112B2 (en) 2016-02-02
RU2586330C2 (ru) 2016-06-10
CA2847293C (fr) 2017-03-28
TW201516039A (zh) 2015-05-01
KR20140054231A (ko) 2014-05-08
US20150031735A1 (en) 2015-01-29
US20160185739A1 (en) 2016-06-30
HK1197239A1 (zh) 2015-01-09

Similar Documents

Publication Publication Date Title
CA2847293C (fr) Formes solides d&#39;un inhibiteur de la dissociation de derives de transthyretine
JP7357525B2 (ja) ６－カルボキシ－２－（３，５－ジクロロフェニル）－ベンゾオキサゾールの結晶性固体形態
AU2019404250B2 (en) Novel polymorphic forms of a TGFβ inhibitor
NZ621194B2 (en) Solid forms of a transthyretin dissociation inhibitor
NZ729011B2 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12780287

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2847293

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20147006603

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012780287

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 231472

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/003043

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014530354

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14345111

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012310157

Country of ref document: AU

Date of ref document: 20120912

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014109676

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014005810

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014005810

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140313